Can you starve cancer?

Caloric restriction and intermittent fasting reduce the availability of glucose, insulin, and insulin-like growth factor 1 (IGF-1) to rapidly dividing cells, including tumor cells. Researchers have proposed that depriving tumors of these energy substrates might slow their growth or enhance the effectiveness of conventional treatments, particularly for cancers that are metabolically driven.

Tumors are metabolically voracious. When overall caloric intake decreases, blood glucose drops, insulin secretion falls, and IGF-1 levels decline, removing hormonal signals that drive cell proliferation. At the same time, caloric restriction activates AMP-activated protein kinase (AMPK) and suppresses the mechanistic target of rapamycin complex 1 (mTORC1), two master regulators of cell growth. This shift triggers autophagy, a cellular recycling process that clears damaged organelles and oncogenic proteins; in normal cells, autophagy may act as a tumor-suppressive mechanism. Fasting also appears to modulate immune surveillance: under caloric restriction, neutrophils have been shown to acquire anti-tumoral properties through pathways that are not yet fully characterized. Separately, intermittent fasting can modulate androgen receptor signaling and reduce systemic inflammation, both of which are relevant to prostate and other hormone-sensitive cancers.

A 2025 scoping review that mapped clinical evidence on fasting-based interventions in cancer patients and survivors found that fasting approaches are increasingly studied as adjuncts to treatment, but concluded that evidence for efficacy, tolerability, and acceptability remains limited and fragmented (PMID 41978091). In a mouse model of triple-negative breast cancer, mild caloric restriction reduced tumor spread and improved chemotherapy response, but voluntary exercise appeared to cancel out the antimetastatic benefit when added to caloric restriction alongside chemotherapy (PMID 42048462). A separate mouse study found that dietary restriction significantly reduced 5-fluorouracil (5-FU)-induced thrombocytopenia in aged animals by improving mitochondrial homeostasis in blood-forming stem cells, suggesting that caloric restriction might help older patients tolerate chemotherapy side effects (PMID 41932340). In hepatocellular carcinoma (HCC) cell models, nutrient restriction enhanced the efficacy of the targeted drug sorafenib by inducing ferroptosis, a form of programmed cell death, through the NRF2/HO-1/GPX4 pathway (PMID 41737774). Research on intermittent fasting and prostate cancer found that fasting-related metabolic changes, including reductions in insulin and IGF-1, may influence androgen receptor activity and splice variant expression, with potential implications for therapy resistance (PMID 41898513). A comprehensive review of dietary interventions and immune function concluded that caloric restriction, intermittent fasting, and fasting-mimicking diets significantly reshape immune cell development and activity, effects that could either help or hinder cancer treatment depending on the context (PMID 41856471). A feasibility trial testing a 6:1 intermittent diet (one low-calorie day per week) for weight gain prevention in women at elevated breast cancer risk is currently underway, highlighting that even fundamental questions of compliance and tolerability are still being answered in this population (PMID 42055614).

Much of the cancer-specific research involves breast cancer, prostate cancer, hepatocellular carcinoma, and renal cell carcinoma. Older patients may have the most to gain from caloric restriction as a strategy for reducing chemotherapy toxicity, since chemotherapy side effects such as low platelet counts are more severe with age. Cancers strongly driven by obesity-related metabolic factors, including excess insulin and IGF-1, may be the most likely candidates for dietary intervention. However, the relationship between fasting protocols and tumor biology is highly cancer-type specific, and benefits seen in one setting do not necessarily translate to others.

Nearly all direct evidence in humans remains early-stage. Most studies are small, short-term feasibility or safety assessments. Animal model results are often promising but have not yet been confirmed in adequately powered randomized controlled trials. Key unknowns include which cancer types respond most, which fasting protocols are most effective, how fasting interacts with specific chemotherapy drugs, and whether the benefits observed in mouse models are relevant to the much longer timeline of human cancer. Confounders such as baseline body composition, cancer stage, concurrent medications, and frailty make it difficult to draw firm conclusions from existing data.

The idea of using dietary strategies to complement cancer treatment is scientifically credible and is an active area of research, but it remains investigational. Evidence suggests that certain fasting approaches may reduce some treatment side effects and potentially slow tumor growth in specific settings, but no dietary intervention has been shown in large randomized trials to replace or substantially augment standard therapy. Anyone considering a fasting or caloric restriction protocol during cancer treatment should discuss it with their oncology team, since effects on drug metabolism and nutrient status can be complex.